Prostatype Genomics AB (PROGEN) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.234x

Based on the latest financial reports, Prostatype Genomics AB (PROGEN) has a cash flow conversion efficiency ratio of -0.234x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-8.54 Million ≈ $-918.99K USD) by net assets (Skr36.48 Million ≈ $3.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Prostatype Genomics AB - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Prostatype Genomics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Prostatype Genomics AB total liabilities for a breakdown of total debt and financial obligations.

Prostatype Genomics AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Prostatype Genomics AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Cipta Selera Murni Pt JK:CSMI	-0.068x
Strategem Capital Corp V:SGE	0.008x
Pittler Maschinenfabrik AG F:PIT	-0.018x
Chiangmai Rimdoi Public Company Limited BK:CRD	-0.023x
Global Sukses Solusi Tbk PT JK:RUNS	-0.002x
Kokoh Inti Arebama Tbk JK:KOIN	-0.605x
Golden Sky Minerals Corp V:AUEN	-0.121x
Sawang Export Public Company Limited BK:SAWANG	-0.029x

Annual Cash Flow Conversion Efficiency for Prostatype Genomics AB (2016–2024)

The table below shows the annual cash flow conversion efficiency of Prostatype Genomics AB from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Prostatype Genomics AB.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr33.47 Million ≈ $3.60 Million	Skr-44.71 Million ≈ $-4.81 Million	-1.336x	-13.12%
2023-12-31	Skr24.67 Million ≈ $2.66 Million	Skr-29.14 Million ≈ $-3.14 Million	-1.181x	-11.52%
2022-12-31	Skr26.15 Million ≈ $2.81 Million	Skr-27.69 Million ≈ $-2.98 Million	-1.059x	-136.49%
2021-12-31	Skr35.91 Million ≈ $3.86 Million	Skr-16.08 Million ≈ $-1.73 Million	-0.448x	+13.89%
2020-12-31	Skr28.29 Million ≈ $3.04 Million	Skr-14.71 Million ≈ $-1.58 Million	-0.520x	+53.85%
2018-12-31	Skr8.55 Million ≈ $919.74K	Skr-9.63 Million ≈ $-1.04 Million	-1.127x	-22.82%
2017-12-31	Skr6.22 Million ≈ $669.69K	Skr-5.71 Million ≈ $-614.46K	-0.918x	-42.21%
2016-12-31	Skr14.93 Million ≈ $1.61 Million	Skr-9.63 Million ≈ $-1.04 Million	-0.645x	--

About Prostatype Genomics AB

ST:PROGEN Sweden Diagnostics & Research

Market Cap

$4.83 Million

Skr44.87 Million SEK

Market Cap Rank

#28433 Global

#645 in Sweden

Share Price

Skr0.76

Change (1 day)

-5.72%

52-Week Range

Skr0.30 - Skr2.50

All Time High

Skr1803.71